|
Information about FDA HIV-related product approvals, safety warnings, notices of upcoming public meetings, and notices about proposed regulatory guidances. Please do not reply to this message. FDA recently granted approval for a fixed dose combination tablet containing 2 nucleoside analogue reverse transcriptase inhibitors, lamivudine/zidovudine 150 mg/300 mg, indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. Please note that this product formulation must be taken on an empty stomach as compared to COMBIVIR and other generic formulations that can be taken without regard to food. Product labeling for this formulation of lamivudine and zidovudine is available at Drugs@FDA. The tablet, manufactured by Pharmacare Limited of South Africa, was Tentatively Approved by FDA on 08/23/2006 for use outside the United States under the PEPFAR program. Richard Klein Steve Morin Kimberly Struble
If you are interested in receiving information about a broader range of FDA topics, consider subscribing to the FDA Patient Network News or Updates for Healthcare Professionals, twice monthly newsletters containing FDA-related information on a variety of topics, including new product approvals, safety warnings, notices of upcoming public meetings, proposed regulatory guidances and opportunity to comment, and other information of interest to patients, patient advocates, and healthcare professionals. Subscriber Services:
| ||||||||||||||||||||||
